Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 16/20 | 0.79 |
| ▸ | PDE4B | Q07343 | 16/20 | 0.79 |
| ▸ | PDE4D | Q08499 | 16/20 | 0.79 |
| ▸ | PDE4C | Q08493 | 15/20 | 0.79 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.72 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.72 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.72 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6358572 | 0.86 | PDE4A (1.00) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL6052681 | 0.84 | PDE4A (0.66) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| Tofimilast SCHEMBL230762 | 0.84 | PDE4A (1.00) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL210263 | 0.81 | PDE4A (1.00) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| Tofimilast SCHEMBL4914697 | 0.78 | PDE4A (0.86) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL7395757 | 0.75 | PDE4A (1.00) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL84865 | 0.75 | PDE4A (1.00) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL14455896 | 0.74 | PDE4A (0.84) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL7374697 | 0.73 | PDE4A (1.00) | PDE4APDE4BPDE4DPDE4CADORA3 | |
| SCHEMBL7398485 | 0.73 | PDE4A (0.96) | PDE4APDE4BPDE4DPDE4CADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147544-A1 | Administering by breathing; antiinflammatory agents; respiratory system disorders | PFIZER INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2003024488-A2 | COMBINATION OF A PDE INHIBITOR AND A LEUKOTRIENE RECEPTOR ANTAGONIST | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147544-A1 | Administering by breathing; antiinflammatory agents; respiratory system disorders | CHRM4, IL4, CHRNA4 | PDE4A 26/4885PDE4B 23/4885PDE4D 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.